IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemia
| Autor: | M. Xolotl-Castillo, Jorge Vela-Ojeda, D. Salazar-Exaire, S. Abraham-Majluf, J. A. Aviña-Zubieta, Jaime García-Chávez, A Rosas-Cabral, M. Vadillo-Buenfil, J. Arenas-Osuna, M. A. García-Ruiz Esparza, Ysabel Padilla-González |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Immunology Lactic dehydrogenase Newly diagnosed Gastroenterology Disease-Free Survival Drug Administration Schedule Prednisone Virology Internal medicine Medicine Humans Objective response Aged Chlorambucil L-Lactate Dehydrogenase business.industry Remission Induction Macroglobulinemia Interferon-alpha Peripheral Nervous System Diseases Cell Biology medicine.disease Fibrosis Recombinant Proteins Surgery Peripheral neuropathy Marrow fibrosis Drug Therapy Combination Female Waldenstrom Macroglobulinemia business medicine.drug |
| Zdroj: | Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 22(10) |
| ISSN: | 1079-9907 |
| Popis: | Waldenström's macroglobulinemia is a rare malignant disorder of B lymphocytes. There are no studies on the use of interferon-alpha (IFN-alpha) as frontline therapy in this disease. Between April 1991 and September 2000, we treated 21 newly diagnosed patients using 8 mg/m(2) chlorambucil and 40 mg/m(2) prednisone p.o. daily for 10 days and 3 megaU/m(2) IFN-alpha three times a week. Patients who responded after induction continued receiving IFN until relapse or death. We found a high frequency of peripheral neuropathy (43%) and grade 3 diffuse marrow fibrosis (43%). Objective response was achieved in 12 (57%) patients, including 4 (19%) complete responders. Median time from treatment to response was 8 months (range 3-18). Median progression-free survival was 70 months (95% CI 47-93), and overall survival was 91 months (95% CI 50-132). Patients who achieved objective response lived longer (91 vs. 33 months, p0.03), as did patients who had lactic dehydrogenase (LDH)180 U/L (89 vs. 54 months, p0.01). Grade 3 hematologic toxicity was observed during induction in 5 patients. IFN-alpha is an effective agent for the induction and maintenance treatment of Waldenström's macroglobulinemia patients. LDH180 U/L and failure to respond are adverse prognostic factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|